Fiche publication
Date publication
février 2016
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
Tous les auteurs :
Spielmann M, Dalenc F, Pointreau Y, Azria D, Classe JM, Dromain C, Facchini T, Gonçalves A, Liegeois P, Namer M, Pivot X, Vincent-Salomon A
Lien Pubmed
Résumé
The prognosis of infracentimetric breast cancers (BC) is heterogeneous. The EURISTIC survey describes how French oncology specialists perceive the prognosis of pT1a,b pN0 BCs. A self-administered questionnaire has been sent to over 2000 French BC specialists. Six hundred and sixty-three physicians responded. Fifty-eight percent do not consider tumor size as a key prognostic criterion. They consider that the cutoff for poor prognosis is 22mm, 10mm and 7mm for hormone receptors (HRs)+, HER2+ and triple-negative (TN) tumors respectively. Eighty-three percent of respondents consider that a HR+ pT1a,b tumor has a good prognosis (21% and 8% for HER2+ and TN respectively). Factors perceived as most detrimental are: HER2 overexpression (29% of respondents); HR- (20%); high grade (20%); TN status (14%); high KI67 (5%); presence of lymphovascular invasion (3%); young age (2%) and high mitotic index (1%). For French specialists, immunohistochemical characteristics, in particular hormone and HER2 status, are strong prognostic factors in BCs below 1cm.
Mots clés
Age Factors, Breast Neoplasms, chemistry, Embolism, complications, Female, France, Humans, Ki-67 Antigen, metabolism, Medical Oncology, statistics & numerical data, Mitotic Index, Perception, Prognosis, Receptor, ErbB-2, metabolism, Receptors, Estrogen, metabolism, Surveys and Questionnaires, Triple Negative Breast Neoplasms, Tumor Burden
Référence
Bull Cancer. 2016 Feb;103(2):154-63
